Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

被引：0

作者：

O'Shaughnessy, J. ^{[1
]}

Wright, G. S. ^{[2
]}

Thummala, A. ^{[3
]}

Danso, M. ^{[4
]}

Popovic, L. S. ^{[5
]}

Pluard, T. ^{[6
]}

Han, H. S. ^{[7
]}

Vojnovic, Z. ^{[8
]}

Vasev, N. ^{[9
]}

Ma, L. ^{[10
]}

Richards, D. A. ^{[11
]}

Wilks, S. ^{[12
]}

Milenkovic, D. M. ^{[13
]}

Sorrentino, J. A. ^{[14
]}

Yang, Z. ^{[15
]}

Horton, J. K. ^{[16
]}

Tan, A. R. ^{[17
]}

机构：

[1] Texas Oncol Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA

[2] Florida Canc Specialists, Oncol, St Petersburg, FL USA

[3] US Oncol Res, Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA

[4] Virginia Oncol Associates, Med Oncol, Norfolk, VA USA

[5] Oncol Inst Vojvodina, Med Oncol, Sremska Kamenica, Serbia

[6] St Lukes Primary Care Plaza, Med Oncol, Kansas City, MO USA

[7] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Breast Oncol, Tampa, FL USA

[8] OB Opca Boln Varazdin Gen Hosp, Dept Oncol, Varazhdin, Croatia

[9] UCRO, Dept Oncol, Skopje, Macedonia

[10] Rocky Mt Canc Ctr LLP, Med Oncol, Denver, CO USA

[11] Texas Oncol PA, Med Oncol, Houston, TX USA

[12] Texas Oncol San Antonio Northeast, Med Oncol, San Antonio, TX USA

[13] Univ Nis, Clin Ctr Nis, Clin Oncol, Nish, Serbia

[14] G1 Therapuet Inc, Translat Med, Res Triangle Pk, NC USA

[15] G1 Therapuet Inc, Biostat, Res Triangle Pk, NC USA

[16] G1 Therapuet Inc, Clin Dev, Res Triangle Pk, NC USA

[17] Atrium Hlth, Levine Canc Inst, Med Oncol, Charlotte, NC USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA22

引用

页码：860 / +

页数：2

共 50 条

[41] Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).
Goel, Shom
O'Shaughnessy, Joyce
Tan, Antoinette R.
Krastev, Boris Milev
Rugo, Hope S.
Aftimos, Philippe Georges
Yardley, Denise A.
Zoran, Andric
Wolfgang, Curt Douglas
Sorrentino, Jessica
Tao, Wenli
Beelen, Andrew Paul
Malik, Rajesh K.
Jain, Sarika
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[42] Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer
Munshi, Pashna Neville
Toppmeyer, Deborah
Wong, Serena Tsan-Lai
Ganesan, Shridar
Tkaczuk, Katherine Hanna
Cianfrocca, Mary E.
Kaklamani, Virginia G.
Gradishar, William John
Somer, Robert A.
Sharan, Kanu
Grana, Generosa
Lerma, Pauline Marie O.
Pliner, Lillian F.
Wieder, Robert
Kane, Michael P.
Kim, Sinae
Tan, Antoinette R.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[43] Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
Park, In Hae
Kong, Sun-Young
Kwon, Youngmee
Kim, Min Kyeong
Sim, Sung Hoon
Joo, Jungnam
Lee, Keun Seok
JOURNAL OF CANCER, 2018, 9 (07): : 1145 - 1151
[44] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
Emens, L.
Adams, S.
Loi, S.
Schmid, P.
Schneeweiss, A.
Rugo, H.
Chui, S.
Winer, E.
CANCER RESEARCH, 2016, 76
[45] Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Denise A. Yardley
Adam Brufsky
Robert E. Coleman
Pierfranco F. Conte
Javier Cortes
Stefan Glück
Jean-Mark A. Nabholtz
Joyce O’Shaughnessy
Robert M. Beck
Amy Ko
Markus F. Renschler
Debora Barton
Nadia Harbeck
Trials, 17
[46] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
Cristiano de Pádua Souza
Ana Suellen Barroso Carneiro
Ana Cecília de Oliveira Lessa
Domício Carvalho Lacerda
Carlos Eduardo Paiva
Marina Moreira Costa Zorzetto
Ana Julia Aguiar de Freitas
Iara Viana Vidigal Santana
Marco Antonio de Oliveira
Edenir Inêz Palmero
Márcia Maria Chiquitelli Marques
Tomás Reinert
Breast Cancer Research and Treatment, 2023, 202 : 57 - 65
[47] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
Souza, Cristiano de Padua
Carneiro, Ana Suellen Barroso
Lessa, Ana Cecilia de Oliveira
Lacerda, Domicio Carvalho
Paiva, Carlos Eduardo
Zorzetto, Marina Moreira Costa
de Freitas, Ana Julia Aguiar
Santana, Iara Viana Vidigal
de Oliveira, Marco Antonio
Palmero, Edenir Inez
Marques, Marcia Maria Chiquitelli
Reinert, Tomas
BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 57 - 65
[48] Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+patients) in metastatic breast cancer patients
Loesch, DM
Asmar, L
McIntyre, KJ
Doane, LL
McKittrick, RJ
Monticelli, MA
Paul, D
Vukelja, SJ
Zhan, F
Boehm, KA
O'Shaughnessy, J
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S280 - S281
[49] A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer
Yardley, Denise A.
Burris, Howard. A., III
Simons, Lisa
Spigel, David R.
Greco, E. Anthony
Barton, John H.
Shipley, Dianna
Drosick, David
Hainsworth, John D.
CLINICAL BREAST CANCER, 2008, 8 (05) : 425 - 431
[50] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan, Yuan
Lee, Jin Sun
Yost, Susan E.
Li, Sierra Min
Frankel, Paul H.
Ruel, Christopher
Schmolze, Daniel
Robinson, Kim
Tang, Aileen
Martinez, Norma
Stewart, Daphne
Waisman, James
Kruper, Laura
Jones, Veronica
Menicucci, Andrea
Uygun, Sahra
Yoder, Erin
van der Baan, Bastiaan
Yim, John H.
Yeon, Christina
Somlo, George
Mortimer, Joanne
ONCOLOGIST, 2021, 26 (03): : E382 - E393

← 1 2 3 4 5 →